title: [The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin].
abstract: The registry of patients treated with Thromboreductin (anagrelide) in the Czech Republic contains data concerning patients that have been treated using this drug since 2004. As of June 2009, the total number of patients was 549. The current analysis focused mainly on evaluation of anagrelide dosage needed to achieve a complete response in high-risk patients: reduction in platelet count to below 400 x 10(9)/l, which was also considered as reaching the therapeutic goal. The outcomes of the registry confirm that although anagrelide (Thromboreductin) is a very effective platelet-reducing agent, the administration of which is related to a low incidence of adverse effects and complications, the therapeutic goal is not achieved in all cases and or despite a quick treatment response, the therapeutic goal is achieved more slowly.
authors.affiliation: Oddelení klinické hematologie FN Brno. m.penka@fnbrno.cz
authors.forename: M
authors.initials: M
authors.lastname: Penka
authors.forename: J
authors.initials: J
authors.lastname: Schwarz
authors.forename: T
authors.initials: T
authors.lastname: Pavlík
authors.forename: K
authors.initials: K
authors.lastname: Indrák
authors.forename: M
authors.initials: M
authors.lastname: Doubek
authors.forename: P
authors.initials: P
authors.lastname: Dulícek
authors.forename: D
authors.initials: D
authors.lastname: Pospísilová
authors.forename: J
authors.initials: J
authors.lastname: Kissová
authors.forename: A
authors.initials: A
authors.lastname: Jonásová
authors.forename: P
authors.initials: P
authors.lastname: Jelínková
authors.forename: A
authors.initials: A
authors.lastname: Hlusí
authors.forename: M
authors.initials: M
authors.lastname: Schutzová
authors.forename: O
authors.initials: O
authors.lastname: Cerná
authors.forename: Y
authors.initials: Y
authors.lastname: Brychtová
authors.forename: L
authors.initials: L
authors.lastname: Nováková
authors.forename: Z
authors.initials: Z
authors.lastname: Korístek
authors.forename: J
authors.initials: J
authors.lastname: Segethová
authors.forename: V
authors.initials: V
authors.lastname: Vozobulová
authors.forename: I
authors.initials: I
authors.lastname: Hadacová
authors.forename: I
authors.initials: I
authors.lastname: Hochová
authors.forename: J
authors.initials: J
authors.lastname: Voglová
authors.forename: L
authors.initials: L
authors.lastname: Walterová
authors.forename: C
authors.initials: C
authors.lastname: Bodzásová
authors.forename: L
authors.initials: L
authors.lastname: Dusek
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000150:complications*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D013920:Thrombocythemia, Essential / Q000188:drug therapy*; D013922:Thrombocytosis / Q000150:complications / Q000188:drug therapy*
chemical_list: D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide